Studies have demonstrated that inhibiting SREBP‐1 mRNA expression reduces cholesterol levels, alleviates hepatic steatosis, and improves adipose tissue hypertrophy, obesity, and insulin resistance. The gene discussed is SREBF1; the disease is obesity due to melanocortin 4 receptor deficiency.